Pacific Biosciences of California, Inc. (PACB) Q3 2022 Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET

Company Participants

Todd Friedman - Director of Investor Relations

Christian Henry - President & Chief Executive Officer

Susan Kim - Chief Financial Officer

Conference Call Participants

Tejas Savant - Morgan Stanley

Julia Qin - JPMorgan

Dan Brennan - Cowen

Kyle Mikson - Canaccord


Hello, and welcome to the PacBio Third Quarter Fiscal Year 2022 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would like now to turn the conference over to Mr. Todd Friedman, Director of Investor Relations. Please go ahead.

Todd Friedman

Good afternoon, and welcome to PacBio Third Quarter 2022 Earnings Conference Call. Earlier today, we issued a press release outlining the financial results we will be discussing on today’s call, a copy of which is available on the Investor’s section of our website at, or as furnished on Form 8-K available on the Securities and Exchange Commission website at

With me today are Christian Henry, President and Chief Executive Officer; and Susan Kim, Chief Financial Officer.

Before we begin, I would like to remind you that on today’s call, we will be making forward-looking statements, including statements regarding predictions, progress, estimates, plans, expectations, intentions, guidance, and others, including expectations regarding our Revio Onso system in their commercialization timeframe.

You should not place undue reliance on forward-looking statements because they are subject to assumptions, and risks, and uncertainties that could cause our actual results to differ materially from those projected or discussed, including those inherent in developing and commercializing new products.

We refer you to the documents that we file with

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.